GlassScriptPhysician profile
Melissa Caro
NPI 1245761139
$2,388.58
in general payments reported to CMS, 2019-2025
25 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $709 · 2023: $301 · 2024: $576 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147 · Travel and Lodging: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.27 |
| Travel and Lodging | $167.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $719.07 | 2021-2024 | |
| Nevro Corp. | $295.14 | 2021-2024 | Senza |
| Globus Medical, INC. | $290.40 | 2025 | Senza |
| Almatica Pharma LLC | $167.36 | 2021-2023 | Gralise |
| Biotronik Nro, INC. | $132.78 | 2024 | Prospera |
| Abbvie INC. | $126.81 | 2023-2024 | |
| Si-Bone, INC. | $91.69 | 2025 | |
| Abbott Laboratories | $91.13 | 2021-2025 | Proclaim, Ionicrf |
| Scilex Pharmaceuticals INC. | $63.82 | 2021-2023 | Ztlido |
| Medtronic, INC. | $61.87 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $44.63 | 2021-2024 | Belbuca |
| Spr Therapeutics, INC | $39.70 | 2024-2025 | Sprint Pns System |
| Lundbeck LLC | $30.29 | 2024 | Vyepti |
| Ultragenyx Pharmaceutical INC. | $26.93 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.32 | 2023 | Ajovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $24.35 | 2021 | |
| Pfizer INC. | $23.62 | 2023 | |
| Relievant Medsystems, INC. | $22.40 | 2021 | |
| Grt US Holding, INC. | $19.52 | 2022 | |
| Ibsa Pharma INC. | $16.98 | 2024 | Tirosint, Licart |
| Lilly USA, LLC | $16.20 | 2021 | |
| Amgen INC. | $15.93 | 2022 | |
| Valinor Pharma, LLC | $15.65 | 2025 | Movantik |
| Allergan, INC. | $15.07 | 2021 | |
| Hikma Pharmaceuticals USA | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.